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Lung transplantation has become an accepted therapy to palliate end-stage lung disease. Broader application is currently limited by ascarcity of suitable donors. Because it is an expensive undertaking,lung transplantation must be regularly evaluated to ensure that it pro-vides value to society and to the patients who may benefit, because“not even the richest countries can now afford to undertake every
health care activity that might conceivably do someone some good somewhere
sometime.”1
In this issue of the Journal, Anyanwu and associates2 present an analysis of the
economic impact of lung transplantation in the United Kingdom. The study com-
pared the costs of 677 thoracic transplantation procedures with the costs accrued by
patients on the waiting list during a 4-year period. From these data Anwanyu and
associates estimated the incremental cost per life-year gained and the cost per qual-
ity-adjusted life-year (QALY) gained. Studies like this often form the basis for
resource allocation decisions. Caution must be exercised in extrapolating these
results to different health care systems in different countries, however, and also in
using this kind of information to allocate resources.
Anwanyu and associates compared the cost of transplantation with the cost of
care for listed patients who had not yet undergone transplantation. However, the
opportunity to transplant a given patient depends on the organ distribution algo-
rithm in place. In the United States, lungs are distributed within geographic regions
primarily according to waiting time. In the United Kingdom, thoracic organs are
distributed to centers on a “rotational” system, with centers possessing considerable
latitude concerning allocation to individuals on their list. It is therefore likely that
as patients become more ill in the United Kingdom, they are more likely to recieve
transplants and thus be removed from the list. Patients on the waiting list are there-
fore not an ideal group to compare costs with transplant recipients. The distribution
algorithm could result in an underestimation of the costs of care for patients with
end-stage lung disease; in turn, this would result in underestimation of the incre-
mental cost of lung transplantation and undervaluing of the transplant procedure. A
fundamental problem of any analysis of incremental costs of a particular therapy
such as lung transplantation is the inescapable fact that death is relatively cheap.
The cost of caring for patients who need a transplant but do not get one is limited
by survival probability without transplantation; as an alternative to transplantation,
death becomes an economic bargain.
Anwanyu and associates assumed that all listed patients were similar in health-
related quality of life (QOL), which was estimated by a separate analysis of 87
patients awaiting lung transplantation who voluntarily answered a questionnaire.3
However, patients awaiting lung transplantation comprise a spectrum, ranging from
those with minimally symptomatic pulmonary hypertension to those in an intensive
care unit with an exacerbation of cystic fibrosis or chronic obstructive pulmonary
disease. In our experience4 patients with cystic fibrosis awaiting lung transplanta-
tion had lower levels of anxiety and used more functional coping strategies than did
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patients with other end-stage lung disease. Similarly,
transplant recipients are not a homogeneous group.
Nevertheless, this study obtained utility data directly from
patients who had end-stage lung disease or who had under-
gone lung transplantation, a method considered superior to
assignment by unaffected individuals or health care
providers.5,6 In fairness, there was no other suitable group
to use as a control, but the additional costs that might have
been incurred by patients with end-stage disease becoming
more ill cannot be taken into account if they are removed
from the list for transplantation.
Anwanyu and associates correctly pointed out that there
is a paucity of studies addressing the cost-utility of lung
transplantation. Some studies have questioned a survival
benefit of lung transplantation, whereas others have shown
clear survival benefit of lung transplantation for US patients
with cystic fibrosis and idiopathic pulmonary fibrosis,
which became apparent after 1 month for patients with cys-
tic fibrosis and 3 months for patients with idiopathic pul-
monary fibrosis.7
The implicit assumption that lung transplantation must
increase life expectancy to be valuable may be flawed. If
transplantation can relieve incapacitating and intolerable
dyspnea, then it may be a reasonable (albeit expensive)
therapy that increases QOL among survivors. With the
growing disparity between donor availability and demand
among lung transplant recipients, however, it may be rea-
sonable to preferentially direct organs toward those judged
more likely to die without lung transplantation. Such an
algorithm for lung distribution is currently under develop-
ment in the United States, and will probably be circulated
for public comment by the United Network for Organ
Sharing (UNOS) soon. This approach attempts to address
the problem of increasing numbers of deaths among
patients on the UNOS lung transplantation waiting list.
Cost-utility analysis seeks to use cost per QALY gained to
guide resource allocation decisions.8 Although this is a valu-
able tool to understand relative costs of various therapies, it
suffers from some limitations. QALY-based comparisons tend
to discriminate against elderly persons, those with reduced life
expectancies, and disabled persons.6,9 Because older people
have a lower life expectancy than do younger people, any life-
saving therapy will understandably result in potentially higher
QALY gains for younger individuals. Is there a useful concept
of “age-achievable QALY?”10 Is a QALY the same value for
a 20-year-old as for a 50-year-old or an 80-year-old? When
asked what is was like to be 90 years old, the late comedian
George Burns reportedly quipped, “It’s better than the alter-
native!” Nord11 argues that people’s interest in and entitle-
ment to continued life may be independent of their health.
Nord and colleagues wrote, “A life year gained should count
as one and no less than one as long as the year is considered
preferable to being dead by the person concerned.”6
In performing cost-utility analyses, economists assume
that society and individuals value current utility higher than
future utility. Thus, future benefits and costs are “dis-
counted,” which represents a value judgment on preference
for current to future consumption. However, it is not clear
that people value future health any less than current health.
A higher discount rate results in less weight to future bene-
fits. Thus, a high discount rate will favor an intervention
that substantially enhances health-related QOL but has little
effect on survival over one that enhances survival but has
little effect on QOL, even if the QALY gains for the two
interventions are identical.9 In the analysis of Anyanwu and
associates, discounting at 6% per year resulted in an
increase in cost per QALY of over 40% (see Table 5 in the
article).2
There are substantial differences among countries in cost
of medical care. Ramsey and coworkers’ pilot study12 early
in the experience of the lung transplantation program in
Seattle determined that the incremental cost per QALY
gained through lung transplantation was $176,817, com-
pared with a range from $29,285 to $48,241 in the UK
study and $71,000 in a Dutch study.13 There are several rea-
sons for cost differences among countries and health care
systems, and there is clearly a difference in various nations’
ability to pay for expensive technologies and, thus, to be
able to afford “expensive” QALYs.
QALYs are not a form of quackery, but any plan to dis-
tribute health care services must take into account the fact
that most people cannot stand idly by when an identified
individual person’s life is threatened if effective rescue
measures are available.14 This “rule of rescue” poses a seri-
ous problem for resource allocation planners because of the
human imperative to rescue life15 and the ethical construct
of distributive justice (what we owe each other).14
By focusing on costs per QALY, we may overlook the
intrinsic value of lung transplantation to our patients and
society as a whole. Thus the quagmire: The fundamental
problem is the assumption that there is a mathematical con-
tinuum between death and excellent health. The tool used
by the investigators to measure QOL in the current study
was the EuroQol EQ5D questionnaire, which allows 243
permutations of health states. A regression equation defines
a utility value for these health states and, when used cor-
rectly, produces an aggregate numeric value for QOL.3 In
our zeal to be objective, have we lost touch with what is
important? How do we put a value on watching another sun-
set, hearing another song, sharing time with a loved one, or
pursuing (and attaining) a lifetime dream? What is the value
of a QALY? There is no concensus regarding the appropri-
ate dollar value per QALY gained on which to base resource
allocation decisions. Estimates of the value of a QALY dif-
fer widely, depending on the approach used to calculate this
value, from $24,777 to $428,286 (median $265,345).16
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What value should we attach to being able to breathe
comfortably? The quality of well-being scale has been used
to measure life quality in patients with cystic fibrosis who
have undergone lung transplantation. If a young adult who
has never enjoyed good health enjoys 9 of the best months
he or she has had in the past decade after a lung transplan-
tation and then dies of a viral illness, what is this worth to
the patient?17 To the family? To society?
We must continue to evaluate the cost-benefit and utility
of our interventions, as Anyanwu and colleagues have
attempted,2 because we may identify strategies to save
money and make expensive therapies more economically
sound. However, we must also be skeptical of efforts to
make cost per QALY the sole determinant of resource allo-
cation in health care. Life is too short, and for some breath-
ing is too difficult.
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